BE2017C021I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C021I2
BE2017C021I2 BE2017C021C BE2017C021C BE2017C021I2 BE 2017C021 I2 BE2017C021 I2 BE 2017C021I2 BE 2017C021 C BE2017C021 C BE 2017C021C BE 2017C021 C BE2017C021 C BE 2017C021C BE 2017C021 I2 BE2017C021 I2 BE 2017C021I2
Authority
BE
Belgium
Application number
BE2017C021C
Other languages
Dutch (nl)
Original Assignee
Sk Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Bioscience Co Ltd filed Critical Sk Bioscience Co Ltd
Publication of BE2017C021I2 publication Critical patent/BE2017C021I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides
BE2017C021C 2003-01-28 2017-06-19 BE2017C021I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/353,753 US7041635B2 (en) 2003-01-28 2003-01-28 Factor VIII polypeptide

Publications (1)

Publication Number Publication Date
BE2017C021I2 true BE2017C021I2 (en) 2023-03-07

Family

ID=32736253

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C021C BE2017C021I2 (en) 2003-01-28 2017-06-19

Country Status (14)

Country Link
US (1) US7041635B2 (en)
EP (2) EP1587832B1 (en)
KR (1) KR100642293B1 (en)
CN (1) CN100404552C (en)
AU (1) AU2003274766B8 (en)
BE (1) BE2017C021I2 (en)
CA (1) CA2514646C (en)
DK (2) DK1587832T3 (en)
ES (1) ES2446041T3 (en)
FR (1) FR17C1024I2 (en)
HK (1) HK1150840A1 (en)
LU (1) LUC00023I2 (en)
NL (1) NL300878I2 (en)
WO (1) WO2004067566A1 (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005055930A2 (en) * 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
EP1765853B1 (en) 2004-01-08 2015-10-28 ratiopharm GmbH O-linked glycosylation of G-CSF peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20110124565A1 (en) * 2005-04-14 2011-05-26 Hans-Peter Hauser Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As Glycopegylated factor ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20090215025A1 (en) 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
WO2008005847A2 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CN101516388B (en) 2006-07-21 2012-10-31 诺和诺德公司 Glycosylation of peptides via O-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As Methods for the purification of polypeptide conjugates
WO2008102923A1 (en) 2007-02-23 2008-08-28 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
WO2009058446A1 (en) * 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
US20100286067A1 (en) * 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
CN101965200B (en) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 Conjugated factor VIII molecules
JP5997443B2 (en) * 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Targeted coagulation factors and methods of using the same
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
EP2470670A4 (en) 2009-08-24 2013-07-10 Amunix Operating Inc Coagulation factor vii compositions and methods of making and using same
WO2011041770A1 (en) 2009-10-02 2011-04-07 The Children's Hospital Of Philadelphia Compositions and methods for enhancing coagulation factor viii function
BR112012013502A2 (en) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "chimeric and hybrid factor viii-fc polypeptides, and methods of using them".
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
PT2591006T (en) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processable single chain molecules and polypeptides made using same
MX351220B (en) * 2010-11-05 2017-10-05 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity.
PT2717898T (en) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Pro-coagulant compounds and methods of use thereof
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EA028914B1 (en) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Assays to monitor bleeding disorders
CN103889445A (en) 2011-10-18 2014-06-25 德国杰特贝林生物制品有限公司 Use of sulfated glycosaminoglycans for improving the bioavailability of Factor VIII
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
KR20140084208A (en) 2011-10-18 2014-07-04 시에스엘 리미티드 Method for improving the stability of purified factor viii after reconstitution
EP2804623B1 (en) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
CN104254614A (en) 2012-01-12 2014-12-31 比奥根艾迪克Ma公司 Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
HUE046848T2 (en) 2012-02-15 2020-03-30 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN104519897A (en) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 Procoagulant compounds
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
KR101395736B1 (en) * 2012-07-10 2014-05-16 아주대학교산학협력단 Human coagulation factor Ⅷdomain specific antibody and method for producing thereof
SG10201701037WA (en) 2012-07-11 2017-03-30 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
RS64664B1 (en) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Optimized factor viii gene
ES2776195T3 (en) 2013-03-15 2020-07-29 Bioverativ Therapeutics Inc Factor VIII polypeptide formulations
TWI745671B (en) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
ES2657291T3 (en) 2013-04-22 2018-03-02 Csl Ltd. A covalent complex of von Willebrand factor and factor VIII associated by a disulfide bridge
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
HUE059820T2 (en) 2014-01-10 2022-12-28 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
JP6778111B2 (en) * 2014-01-20 2020-10-28 オクタファルマ・アーゲー A method for producing Factor VIII with an improved ratio of FVIII: C / FVIII: Ag
KR20230136616A (en) 2014-02-04 2023-09-26 바이오젠 엠에이 인코포레이티드 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN106687126B (en) 2014-08-04 2020-07-28 杰特有限公司 Factor VIII formulations
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
JP2018510212A (en) 2015-03-06 2018-04-12 ツェー・エス・エル・ベーリング・レコンビナント・ファシリティ・アクチエンゲゼルシャフト Modified von Willebrand factor with improved half-life
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
JP6909203B2 (en) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド Factor IX fusion proteins and their production and usage
WO2017050820A1 (en) * 2015-09-22 2017-03-30 Novo Nordisk A/S Fviii fusion proteins
EA036944B1 (en) 2015-11-13 2021-01-19 Баксалта Инкорпорейтед Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
JP6768798B2 (en) 2015-11-13 2020-10-14 バクスアルタ インコーポレイテッド Highly expressed viral vector for the treatment of hemophilia A gene encoding a recombinant FVIII variant
MX2018008337A (en) 2016-01-07 2018-09-17 CSL Behring Lengnau AG Mutated truncated von willebrand factor.
JP7217630B2 (en) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド Optimized Factor VIII gene
JP7235511B2 (en) 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ Recombinant single-chain FVIII and chemical conjugates thereof
US11046749B2 (en) 2016-06-24 2021-06-29 Mogam Institute For Biomedical Research Chimera protein comprising FVIII and vWF factors, and use thereof
JP6351679B2 (en) * 2016-09-30 2018-07-04 エスケー ケミカルズ カンパニー リミテッド Method for producing and purifying factor VIII and its derivatives
WO2018087267A1 (en) 2016-11-11 2018-05-17 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CN110381986B (en) 2016-11-11 2023-08-18 康诺贝林伦瑙有限公司 Truncated von willebrand factor polypeptides for extravascular administration to treat or prevent coagulation disorders
MX2019006446A (en) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Methods of inducing immune tolerance to clotting factors.
JP2020500874A (en) 2016-12-02 2020-01-16 バイオベラティブ セラピューティクス インコーポレイテッド Method of treating hemophilic arthropathy using chimeric clotting factor
US11141466B2 (en) 2017-06-22 2021-10-12 CSL Behring Lengnau AG Modulation of FVIII immunogenicity by truncated VWF
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
CN111295094A (en) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 Freeze-drying container and method for using freeze-drying container
EP3746136A1 (en) 2018-02-01 2020-12-09 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
EP3773517A1 (en) 2018-04-04 2021-02-17 Sigilon Therapeutics, Inc. Implantable particles and related methods
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
MX2021000582A (en) 2018-07-16 2021-04-12 Baxalta Inc Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression.
CN113227385A (en) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use for non-viral gene therapy
EP3852780A1 (en) * 2018-09-19 2021-07-28 Cell Machines, Inc. Methods and compositions related to improved factor viii long half-life coagulation complexes
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
TW202039546A (en) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
MA54951A (en) 2019-02-15 2021-12-22 Bayer Healthcare Llc GENE EDITING FOR HEMOPHILIA A WITH ENHANCED FACTOR VIII EXPRESSION
WO2020185916A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
TW202115127A (en) 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 Methods and compositions for treating hemophilia and low bone mineral density
US20220389082A1 (en) 2019-07-04 2022-12-08 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
EP4073106A2 (en) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP2021156833A (en) 2020-03-30 2021-10-07 シスメックス株式会社 Measuring method of blood coagulation activity
EP4355768A1 (en) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AR126846A1 (en) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENES
TW202346327A (en) 2021-09-30 2023-12-01 美商百歐維拉提夫治療公司 Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3683980D1 (en) 1985-04-12 1992-04-02 Genetics Inst NEW PROCOAGULATION PROTEINS.
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
FR2619314B1 (en) 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
EP1397496A2 (en) 2001-06-15 2004-03-17 Andre Schuh Gene therapy for hemophilia a

Also Published As

Publication number Publication date
EP2253645A3 (en) 2011-02-16
WO2004067566A1 (en) 2004-08-12
AU2003274766A1 (en) 2004-08-23
CA2514646C (en) 2013-07-23
DK2253645T3 (en) 2016-06-27
FR17C1024I2 (en) 2019-07-19
LUC00023I2 (en) 2017-09-08
US7041635B2 (en) 2006-05-09
AU2003274766B8 (en) 2009-08-27
HK1150840A1 (en) 2012-01-13
LUC00023I1 (en) 2017-06-21
NL300878I2 (en) 2017-11-02
FR17C1024I1 (en) 2017-09-08
DK1587832T3 (en) 2014-02-24
EP2253645B1 (en) 2016-03-23
AU2003274766B2 (en) 2009-02-12
CN1745100A (en) 2006-03-08
KR100642293B1 (en) 2006-11-03
CA2514646A1 (en) 2004-08-12
CN100404552C (en) 2008-07-23
KR20050044776A (en) 2005-05-12
US20040147436A1 (en) 2004-07-29
EP1587832A1 (en) 2005-10-26
EP1587832B1 (en) 2013-12-11
EP2253645A2 (en) 2010-11-24
ES2446041T3 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
BE2017C021I2 (en)
BE2015C007I2 (en)
BE2014C055I2 (en)
BE2014C027I2 (en)
BE2014C003I2 (en)
BE2013C075I2 (en)
BE2013C070I2 (en)
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
BE2011C030I2 (en)
JP2004152265A5 (en)
JP2004029744A5 (en)
BE2015C005I2 (en)
BE2012C053I2 (en)
JP2003299632A5 (en)
JP2003288983A5 (en)
JP2003249721A5 (en)
DE602004016566D1 (en)
JP2004216818A5 (en)
JP2003274334A5 (en)
JP2004226678A5 (en)
JP2003297751A5 (en)
JP2004228510A5 (en)
JP2004103585A5 (en)